- Home
- CRS vs EXEL Comparison
CRS vs EXEL Comparison
Compare CRS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRS
- EXEL
- Stock Information
- Founded
- CRS 1910
- EXEL 1994
- Country
- CRS United States
- EXEL United States
- Employees
- CRS N/A
- EXEL N/A
- Industry
- CRS Steel/Iron Ore
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRS Industrials
- EXEL Health Care
- Exchange
- CRS Nasdaq
- EXEL Nasdaq
- Market Cap
- CRS 8.9B
- EXEL 9.7B
- IPO Year
- CRS N/A
- EXEL 2000
- Fundamental
- Price
- CRS $206.58
- EXEL $36.20
- Analyst Decision
- CRS Buy
- EXEL Buy
- Analyst Count
- CRS 6
- EXEL 17
- Target Price
- CRS $153.00
- EXEL $35.50
- AVG Volume (30 Days)
- CRS 1.1M
- EXEL 2.4M
- Earning Date
- CRS 01-30-2025
- EXEL 02-04-2025
- Dividend Yield
- CRS 0.39%
- EXEL N/A
- EPS Growth
- CRS 108.18
- EXEL 441.02
- EPS
- CRS 4.49
- EXEL 1.55
- Revenue
- CRS $2,825,400,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- CRS $10.77
- EXEL $20.53
- Revenue Next Year
- CRS $7.95
- EXEL $0.95
- P/E Ratio
- CRS $45.98
- EXEL $23.33
- Revenue Growth
- CRS 5.45
- EXEL 17.31
- 52 Week Low
- CRS $58.87
- EXEL $20.02
- 52 Week High
- CRS $207.99
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- CRS 73.95
- EXEL 58.54
- Support Level
- CRS $175.34
- EXEL $33.05
- Resistance Level
- CRS $202.25
- EXEL $37.59
- Average True Range (ATR)
- CRS 6.39
- EXEL 0.99
- MACD
- CRS 3.18
- EXEL 0.28
- Stochastic Oscillator
- CRS 96.71
- EXEL 69.38
About CRS Carpenter Technology Corporation
Carpenter Technology Corp supplies specialty metals to a variety of end markets, including aerospace and defense, industrial machinery and consumer durables, medical, and energy, among others. The company's reportable segments include; Specialty Alloys Operations and Performance Engineered Products. It generates maximum revenue from the Specialty Alloys Operations segment. The SAO segment is comprised of the company's alloy and stainless steel manufacturing operations. This includes operations performed at mills predominantly in Reading and Latrobe, Pennsylvania, and surrounding areas as well as South Carolina and Alabama. Geographically, the company derives its maximum revenue from the United States and the rest from Europe, Asia Pacific, Mexico, Canada, and other regions.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.